An ASCO leadership development project to understand barriers to clinical cancer research in the Asia-Pacific. Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy ...
Identification of factors related to immunotherapy prognosis in patients with advanced head and neck squamous cell carcinoma. MVX-ONCO-1 in advanced refractory cancers: Safety, feasibility, and ...
Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...
ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results